510(k) Report

510(k) · Cleared

Cleared

Carbamazepine Gen 4

K151578510(k) TraditionalCleared Oct 22, 2015133-day reviewClass II21 CFR 862.3645

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Roche Diagnostics Operations (Rdo) · KLT Enzyme Immunoassay, Carbamazepine

Cleared on Oct 22, 2015 as substantially equivalent to K031902 (Roche Diagnostics Corp., 2003) after a 133-day review. Its family tree reaches back 2 generations to 1995.

Decided
Oct 22, 2015
Review
133 days
Class
Class II
Product code
KLT
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K951595 (1995). No later device cites it as a predicate yet.

  1. Root · 2 generations backK951595 Roche Cobas Integra Analyzer, Reagent CassettesRoche Diagnostic Systems, Inc. · 1995 · Recalled
  2. 1 generation backK031902 Online TDM CarbamazepineRoche Diagnostics Corp. · 2003
  3. This deviceK151578 Carbamazepine Gen 4Roche Diagnostics Operations (Rdo) · 2015
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K951595Roche Cobas Integra Analyzer, Reagent CassettesRoche Diagnostic Systems, Inc.19957
−1K031902Online TDM CarbamazepineRoche Diagnostics Corp.2003—
0 (this device)K151578Carbamazepine Gen 4Roche Diagnostics Operations (Rdo)2015—
FIG. 1 — Lineage of K151578, 1995–2015Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KLT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K031902Online TDM Carbamazepine
Summary page 4
…ame Neuroleptic drugs radioreceptor assay test system Product Codes KLT, 21 CFR § 862.3645 Predicate Devices ONLINE TDM Carbamazepine, K031902 Establishment Registration 1823260, Roche Diagnostics Corporation…
Roche Diagnostics Corp.2003—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 20 years and passes through 3 companies; a new generation was cleared every 12.1 years on median.
  • 1 of the 2 ancestors has a recall of any class.

How does its category compare?

All KLT devices

KLT Enzyme Immunoassay, Carbamazepine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2015, this device’s year, is highlighted.

FDA decisions per year · KLT

1in 2015

2007: 12011: 12013: 12015: 1
2007high 1 (2007) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KLT

Too few KLT 510(k)s in any year since 2007 to give a median.

Recalls per year · KLT

1in 2013

2013: 1
2007high 1 (2013) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KLT

4in 2025

2009: 22010: 12011: 12012: 12013: 12014: 32015: 92016: 32017: 12018: 42019: 62020: 12021: 22022: 72023: 32024: 12025: 4
2007high 9 (2015) · low 0 (2007)2025

MAUDE reports naming product code KLT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20080—00
20090—02
20100—01
20111—01
20120—01
20131—11
20140—03
20151—09
20160—03
20170—01
20180—04
20190—06
20200—01
20210—02
20220—07
20230—03
20240—01
20250—04
20260—0—

What is it indicated for?

In vitro test for the quantitative determination of carbamazepine in serum and plasma on Roche/Hitachi cobas c systems.

Measurements obtained are used in monitoring levels of carbamazepine to help ensure appropriate therapy.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K151578: Carbamazepine Gen 4.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K151578

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026